Li-Fraumeni syndrome: Report of a clinical research workshop and creation of a research consortium

Cancer Genetics

Volumn 205, Issue 10, 2012, Pages 479-487

  Mai, Phuong L ^a   Malkin, David ^b   Garber, Judy E ^c   Schiffman, Joshua D ^d   Weitzel, Jeffrey N ^e   Strong, Louise C ^f   Wyss, Oliver ^g   Locke, Luana ^g   Means, Von ^g   Achatz, Maria Isabel ^h   Hainaut, Pierre ⁱ   Frebourg, Thierry ^j   Evans, D Gareth ^k   Bleiker, Eveline ^l   Patenaude, Andrea ^m   Schneider, Katherine ^c   Wilfond, Benjamin ⁿ   Peters, June A ^a   Hwang, Paul M ^o   Ford, James ^p   Tabori, Uri ^j   Ognjanovic, Simona ^q   Dennis, Phillip A ^a   Wentzensen, Ingrid M ^a   Greene, Mark H ^a   Fraumeni, Joseph F ^a   Savage, Sharon A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Hospital AC Camargo and National Institute of Science and Technology in Oncogenomics ^*

^h A C CAMARGO CANCER CENTER   (Brazil)

ⁱ INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^j INSERM   (France)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^o NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^p STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

Hereditary cancer predisposition syndrome; Li Fraumeni syndrome; TP53 mutations

Indexed keywords

ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGISTRY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHILDHOOD CANCER; COLONOSCOPY; FAMILIAL CANCER; FAMILY COUNSELING; FAMILY HISTORY; FAMILY STUDY; GENE MUTATION; GENETIC COUNSELING; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GERM LINE; HEALTH PROGRAM; HETEROZYGOTE; HISTORY OF MEDICINE; HUMAN; INHERITANCE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT ADVOCACY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; RISK REDUCTION; SECOND CANCER; SOCIAL PSYCHOLOGY; TUMOR SUPPRESSOR GENE; UNITED STATES;

CONGRESSES AS TOPIC; FAMILY HEALTH; FEMALE; GENES, P53; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; MALE; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; PROGRAM DEVELOPMENT; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 84867671998     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.06.008     Document Type: Article

References (41)

1. Palmero E.I., Achatz M.I., Ashton-Prolla P., et al. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 2010, 22:64-69.
2. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
3. Srivastava S., Zou Z.Q., Pirollo K., et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990, 348:747-749.
4. Li F.P., Fraumeni J.F.J. Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome?. Ann Intern Med 1969, 71:747-752.
5. Lustbader E.D., Williams W.R., Bondy M.L., et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992, 51:344-356.
6. Fang S., Krahe R., Lozano G., et al. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 2010, 5:e10813. doi: 10810.11371/journal.pone.0010813.
7. Hwang S.J., Lozano G., Amos C.I., et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003, 72:975-983.
8. Gonzalez K.D., Noltner K.A., Buzin C.H., et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27:1250-1256.
9. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358-5362.
10. Garber J.E., Goldstein A.M., Kantor A.F., et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991, 51:6094-6097.
11. Birch J.M., Hartley A.L., Tricker K.J., et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54:1298-1304.
12. Eeles R.A. Germline mutations in the TP53 gene. Cancer Surv 1995, 25:101-124.
13. Varley J.M. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003, 21:313-320.
14. Olivier M., Eeles R., Hollstein M., et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19:607-614.
15. Chompret A., Abel A., Stoppa-Lyonnet D., et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001, 38:43-47.
16. Tinat J., Bougeard G., Baert-Desurmont S., et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27:e108-e109. author reply e110.
17. Bougeard G., Sesboue R., Baert-Desurmont S., et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008, 45:535-538.
18. Wu C.C., Strong L.C., Shete S. Effects of measured susceptibility genes on cancer risk in family studies. Hum Genet 2010, 127:349-357.
19. Achatz M.I.W., Hainaut P., Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?. Lancet Oncol 2009, 10:920-925.
20. Achatz M.I.W., Olivier M., Calvez F.L., et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007, 245:96-102.
21. Palmero E.I., Schuler-Faccini L., Caleffi M., et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008, 261:21-25.
22. Garritano S., Gemignani F., Palmero E.I., et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010, 31:143-150.
23. Ribeiro R.C., Sandrini F., Figueiredo B., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 2001, 98:9330-9335.
24. Varley J.M., McGown G., Thorncroft M., et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 1999, 65:995-1006.
25. Evans D.G., Moran A., Hartley R., et al. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer 2010, 102:1091-1098.
26. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57:75-89.
27. Masciari S., Van den Abbeele A.D., Diller L.R., et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 2008, 299:1315-1319.
28. Villani A., Tabori U., Schiffman J., et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011, 12:559-567.
29. Matoba S., Kang J.G., Patino W.D., et al. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
30. Sung H.J., Ma W., Wang P.-Y., et al. Mitochondrial respiration protects against oxygen-associated DNA damage. Nat Commun 2010, 1:1-8.
31. Bensaad K., Tsuruta A., Selak M.A., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
32. Marcel V., Palmero E.I., Falagan-Lotsch P., et al. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 2009, 46:766-772.
33. Tabori U., Nanda S., Druker H., et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007, 67:1415-1418.
34. Trkova M., Prochazkova K., Krutilkova V., et al. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. Cancer 2007, 110:694-702.
35. Shlien A., Tabori U., Marshall C.R., et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A 2008, 105:11264-11269.
36. Tabori U., Malkin D. Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 2008, 68:2053-2057.
37. Petitjean A., Achatz M.I., Borresen-Dale A.L., et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26:2157-2165.
38. Lalloo F., Varley J., Moran A., et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006, 42:1143-1150.
39. Lammens C.R.M., Aaronson N.K., Wagner A., et al. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 2010, 28:3008-3014.
40. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 2005, 14:1060-1074.
41. Lammens C.R., Bleiker E.M., Aaronson N.K., et al. Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits. Fam Cancer 2010, 9:647-654.